Science

Maximilian Merz: What is the biology behind CAR+ T-cell lymphomas?

Maximilian Merz/roswellpark.org

Feb 25, 2025, 08:29

Maximilian Merz: What is the biology behind CAR+ T-cell lymphomas?

Maximilian Merz, Head of Early Clinical Trials Unit Leipzig (ECTUL) at Leipzig University, shared an article by Till Braun, et al. on LinkedIn:

“What is the biology behind CAR+ T-cell lymphomas?

Please check out our latest article in Nature Medicine in which we explored together with the amazing colleagues from the University of Cologne and the Fraunhofer IZI a rare case of a myeloma patient who developed a CAR+ indolent T-cell lymphoma with features of a T-LGLL after CAR T cell therapy.

Thanks to my fellow co-first authors, the irresistible Till Braun and Michael Rade as well as senior authors Kristin Reiche, Marco Herling and Tim Richardson.

Such a great collaboration between three institutions to decipher an extremely intriguing case. Many thanks to the heads of the departments Michael Hallek, Ulrike Köhl and Uwe Platzbecker for supporting this warp speed effort!”

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.

Authors: Till Braun, et al.

biology cancer CAR T-cell therapy Early Clinical Trials Unit Leipzig fight against cancer Fraunhofer IZI Global fight against cancer Kristin Reiche Leipzig University Marco Herling Maximilian Merz Michael Hallek Michael Rade Myeloma Nature Medicine OncoDaily Oncology T-cell lymphomas Till Braun Tim Richardson Ulrike Köhl University of Cologne Uwe Platzbecker

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC